RETA/CAG on its own record
RETA/CAG is a dual-peptide research blend of retatrutide and cagrilintide in a single lyophilised presentation — not a dual-strength GLP-3 RT kit. As a composite material it has no single CAS number. VaultLabs supplies RETA/CAG for in vitro laboratory research only.
Composition: Retatrutide 12.5 mg + cagrilintide 2.5 mg.
CAS number: Not applicable — composite material.
Appearance: White to off-white lyophilised blend.
Catalog strength: 15 mg total fill.
Retatrutide + Cagrilintide 15mg (RETA/CAG) is the 15 mg blend lyophilized unit, listed at AED 649 before VAT. The product record stores that sealed unit at 2–8 °C · protect from light.
How RETA/CAG differs from the linked records
RETA/CAG versus Retatrutide. RETA/CAG is catalogued as a Dual-peptide research blend. Retatrutide is catalogued as a Multi-receptor agonist peptide (research literature) (Metabolic pathway research). They are separate records. RETA/CAG is listed with CAS Not applicable — composite material. Retatrutide is listed with CAS 2381089-83-2. A certificate for Retatrutide does not qualify a RETA/CAG vial, and the reverse is also true. Read Retatrutide on its own monograph rather than inferring it from this page.
RETA/CAG versus Tirzepatide. RETA/CAG is catalogued as a Dual-peptide research blend. Tirzepatide is catalogued as a Incretin dual-agonist peptide (Metabolic & incretin research). They are separate records. RETA/CAG is listed with CAS Not applicable — composite material. Tirzepatide is listed with CAS 2023788-19-2. A certificate for Tirzepatide does not qualify a RETA/CAG vial, and the reverse is also true. Read Tirzepatide on its own monograph rather than inferring it from this page.
RETA/CAG versus Semaglutide. RETA/CAG is catalogued as a Dual-peptide research blend. Semaglutide is catalogued as a Incretin GLP-1 agonist peptide (Metabolic & incretin research). They are separate records. RETA/CAG is listed with CAS Not applicable — composite material. Semaglutide is listed with CAS 910463-68-2. A certificate for Semaglutide does not qualify a RETA/CAG vial, and the reverse is also true. Read Semaglutide on its own monograph rather than inferring it from this page.
Certificates do not cross over
Lot VL-RETACAG-20260801 is the catalogue certificate for Retatrutide + Cagrilintide 15mg (RETA/CAG). Read it on Retatrutide + Cagrilintide 15mg (RETA/CAG) certificate and match the vial in batch verification. A certificate for a different strength, or for a blend that merely contains the same name, does not release this unit.
If a purchase order says RETA/CAG, a vial of a related compound does not satisfy it. If the order names a strength, a different strength of RETA/CAG does not satisfy it either.
What this comparison refuses to do
It does not rank RETA/CAG against another material, recommend a combination, or translate a paper into a dose. VaultLabs does not provide dosage, administration, study-design, or medical guidance.
Prices and the literature notes are on the RETA/CAG research summary. Sealed-unit handling is the RETA/CAG storage guide. The RETA/CAG compound monograph remains the long record.
VaultLabs dispatches RETA/CAG from Dubai. Orders leave fulfillment within 24 hours, 7 days a week. Standard delivery is AED 35 to every emirate, and delivery is free when the post-discount merchandise subtotal is AED 500 or more. Checkout shows the fee for the address entered. All VaultLabs products are supplied strictly for laboratory and research use only. They are not intended for human consumption, medical use, personal use, or diagnostic use. VaultLabs does not provide dosage, administration, study-design, or medical guidance.